M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics
Abstract Background N6-methyladenosine (m6A) methylation modification is involved in the regulation of various biological processes, including inflammation, antitumor, and antiviral immunity. However, the role of m6A modification in the pathogenesis of autoimmune diseases has been rarely reported. M...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-023-03149-w |
| _version_ | 1797451929307054080 |
|---|---|
| author | Yurong Huang Qiuyun Xue Jun Chang Yuting Wang Chenglong Cheng Suowen Xu Xiao Wang Chenggui Miao |
| author_facet | Yurong Huang Qiuyun Xue Jun Chang Yuting Wang Chenglong Cheng Suowen Xu Xiao Wang Chenggui Miao |
| author_sort | Yurong Huang |
| collection | DOAJ |
| description | Abstract Background N6-methyladenosine (m6A) methylation modification is involved in the regulation of various biological processes, including inflammation, antitumor, and antiviral immunity. However, the role of m6A modification in the pathogenesis of autoimmune diseases has been rarely reported. Methods Based on a description of m6A modification and the corresponding research methods, this review systematically summarizes current insights into the mechanism of m6A methylation modification in autoimmune diseases, especially its contribution to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Results By regulating different biological processes, m6A methylation is involved in the pathogenesis of autoimmune diseases and provides a promising biomarker for the diagnosis and treatment of such diseases. Notably, m6A methylation modification is involved in regulating a variety of immune cells and mitochondrial energy metabolism. In addition, m6A methylation modification plays a role in the pathological processes of RA, and m6A methylation-related genes can be used as potential targets in RA therapy. Conclusions M6A methylation modification plays an important role in autoimmune pathological processes such as RA and SLE and represents a promising new target for clinical diagnosis and treatment, providing new ideas for the treatment of autoimmune diseases by targeting m6A modification-related pathways. |
| first_indexed | 2024-03-09T15:01:33Z |
| format | Article |
| id | doaj.art-f44ad434ad6d48e0b3c01456a0eae403 |
| institution | Directory Open Access Journal |
| issn | 1478-6362 |
| language | English |
| last_indexed | 2024-03-09T15:01:33Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj.art-f44ad434ad6d48e0b3c01456a0eae4032023-11-26T13:54:29ZengBMCArthritis Research & Therapy1478-63622023-10-0125111510.1186/s13075-023-03149-wM6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigeneticsYurong Huang0Qiuyun Xue1Jun Chang2Yuting Wang3Chenglong Cheng4Suowen Xu5Xiao Wang6Chenggui Miao7Department of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese MedicineDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese MedicineDepartment of Orthopaedics, the First Affiliated Hospital, Anhui Medical UniversityDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese MedicineDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese MedicineDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of ChinaDepartment of Clinical Nursing, School of Nursing, Anhui University of Chinese MedicineDepartment of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese MedicineAbstract Background N6-methyladenosine (m6A) methylation modification is involved in the regulation of various biological processes, including inflammation, antitumor, and antiviral immunity. However, the role of m6A modification in the pathogenesis of autoimmune diseases has been rarely reported. Methods Based on a description of m6A modification and the corresponding research methods, this review systematically summarizes current insights into the mechanism of m6A methylation modification in autoimmune diseases, especially its contribution to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Results By regulating different biological processes, m6A methylation is involved in the pathogenesis of autoimmune diseases and provides a promising biomarker for the diagnosis and treatment of such diseases. Notably, m6A methylation modification is involved in regulating a variety of immune cells and mitochondrial energy metabolism. In addition, m6A methylation modification plays a role in the pathological processes of RA, and m6A methylation-related genes can be used as potential targets in RA therapy. Conclusions M6A methylation modification plays an important role in autoimmune pathological processes such as RA and SLE and represents a promising new target for clinical diagnosis and treatment, providing new ideas for the treatment of autoimmune diseases by targeting m6A modification-related pathways.https://doi.org/10.1186/s13075-023-03149-wm6a methylation modificationMethylation regulationAutoimmune diseasesRheumatoid arthritisSystemic lupus erythematosus |
| spellingShingle | Yurong Huang Qiuyun Xue Jun Chang Yuting Wang Chenglong Cheng Suowen Xu Xiao Wang Chenggui Miao M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics Arthritis Research & Therapy m6a methylation modification Methylation regulation Autoimmune diseases Rheumatoid arthritis Systemic lupus erythematosus |
| title | M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics |
| title_full | M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics |
| title_fullStr | M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics |
| title_full_unstemmed | M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics |
| title_short | M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics |
| title_sort | m6a methylation modification in autoimmune diseases a promising treatment strategy based on epigenetics |
| topic | m6a methylation modification Methylation regulation Autoimmune diseases Rheumatoid arthritis Systemic lupus erythematosus |
| url | https://doi.org/10.1186/s13075-023-03149-w |
| work_keys_str_mv | AT yuronghuang m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT qiuyunxue m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT junchang m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT yutingwang m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT chenglongcheng m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT suowenxu m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT xiaowang m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics AT chengguimiao m6amethylationmodificationinautoimmunediseasesapromisingtreatmentstrategybasedonepigenetics |